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Abstract 
Melphalan at a dose of 200mg/m
2
 is standard conditioning prior to autologous haematopoietic stem cell 
transplantation for multiple myeloma, but a dose of 140mg/m
2
 is often used in clinical practice in 
patients perceived to be at risk of excess toxicity. To determine if melphalan 200 and melphalan 140 are 
equally effective and tolerable in clinically relevant patient subgroups we analysed 1964 first single 
autologous transplantation episodes using a series of Cox proportional-hazards models. Overall survival, 
progression-free survival, cumulative incidence of relapse, non-relapse mortality, haematopoietic 
recovery and second primary malignancy rates were not significantly different between the melphalan 
140 (n=245) and melphalan 200 (n=1719) groups. Multivariable subgroup analysis showed that disease 
status at transplantation interacted with overall survival, progression-free survival, and cumulative 
incidence of relapse, with a significant advantage associated with melphalan 200 in patients 
transplanted in less than partial response (adjusted hazard ratios for melphalan 200 versus melphalan 
140: 0.5, 0.54, and 0.56). In contrast, transplantation in very good partial or complete response 
significantly favoured melphalan 140 for overall survival (adjusted hazard ratio: 2.02). Age, renal 
function, prior proteasome inhibitor treatment, gender, or Karnofsky score did not interact with 
overall/progression-free survival or relapse rate in the melphalan dose groups. There were no 
significant survival or relapse rate differences between melphalan 200 and melphalan 140 patients with 
high-risk or standard-risk chromosomal abnormalities. In conclusion, remission status at the time of 
transplantation may favour melphalan 200 or melphalan 140 for key transplant outcomes 
(NCT01362972). 
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Introduction 
High-dose chemotherapy followed by autologous haematopoietic stem cell transplantation (ASCT) has 
been the standard consolidation treatment for newly diagnosed multiple myeloma patients up to the 
age of 65 years for over two decades. Initially, high-dose chemotherapy plus ASCT proved superior to 
conventional chemotherapy.
1,2
 More recently, the benefit of upfront high-dose chemotherapy plus ASCT 
has been confirmed in treatment approaches incorporating thalidomide analogues and proteasome 
inhibitors.
3-6
 High-dose chemotherapy plus ASCT is also commonly used in older patients over the age of 
65 years.
7,8
 However, the superiority of ASCT over non-intensive therapies in older patients remains to 
be established.
9,10
 
In the trials that demonstrated superiority of autologous transplantation over non-intensive 
approaches, patients received high-dose chemotherapy with melphalan at a dose of 200mg/m
2 
(Mel200).
1-6
 Mel200 was less toxic than other high-dose combination regimens
11,12
 and associated with 
longer progression-free survival (PFS), and overall survival in patients younger than 60 years, when 
compared to melphalan 100mg/m
2
 in a tandem transplant approach.
13
 Mel200 has therefore been 
recommended and widely used as standard conditioning therapy for ASCT.
14-16
 Some studies have linked 
Mel200 to excess toxicity in older patients and those with renal impairment.
17-19
 A dose of 140mg/m
2
 
(Mel140) is therefore widely used in clinical practice in older patients and in patients with renal 
impairment.
20-25
 However, Mel140 was associated with inferior response or survival rates compared to 
Mel200 in two very recent studies.
24,26
 It therefore remains to be determined whether Mel140 and 
Mel200 are equally effective and tolerable across patient subgroups. 
To address this question we analysed outcomes of almost 2000 first single autologous transplants for 
multiple myeloma after conditioning with either Mel140 or Mel200 that were reported to the European 
Society for Blood and Marrow Transplantation (EBMT). The results of the study indicate that the 
selection of Mel200 versus Mel140 may have a significant effect on key transplant outcomes, including 
overall survival. 
Methods 
Study criteria and data management 
The Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study 
(NCT01362972) is an observational clinical outcome analysis of a defined cohort of patients with 
lymphoma or multiple myeloma who underwent ASCT between 2008 and 2012, with data reported 
retrospectively to the EBMT. Patients were eligible for the CALM study if they were ≥18 years old and 
received their first autologous peripheral blood stem cell transplant using cells mobilised with one of 
the following mobilization regimens: plerixafor plus G-CSF, plerixafor plus G-CSF plus chemotherapy, G-
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CSF plus chemotherapy, or G-CSF alone. For this non-planned subgroup analysis, patient were selected 
from the CALM study population in the EBMT registry if they had a diagnosis of multiple myeloma and 
received a first single ASCT. Tandem transplants (defined as an ASCT followed by a 2
nd
  transplant within 
6 months of the first and no relapse/progression between the two transplants), and patients who 
received melphalan doses other than 200 or 140mg/m
2
, were not included. A total of 2253 patients 
from the CALM study EBMT registry fulfilled these general criteria. We excluded 289 of these patients 
from further analysis because of missing or inconclusive data regarding subsequent transplants (n=213), 
relapse date (n=67), or renal function (n=9), resulting in a final study population of 1964. The data base 
for this study was closed on December 14
th
 2016.  
The study was performed in accordance with the principles of the Declaration of Helsinki and approved 
by the Chronic Malignancies Working Party of the EBMT, a non-profit scientific society representing 
more than 600 transplant centres mainly located in Europe. Data reported to the EBMT are entered, 
managed, and maintained in a central database with internet access that is housed in Leiden University 
Medical Centre, The Netherlands. Each EBMT centre is represented in this database, and all patients 
whose transplant data are reported by participating centers provide informed consent for transplant-
related data to be used for research purposes in an anonymous way. 
Statistical analysis 
Patients’ characteristics between the two groups Mel140 and Mel200 were compared using the  
 
 test 
for categorical variables and the Mann-Whitney test for continuous variables. P-values for variables with 
more than two levels refer to an overall test for the presence of any difference. Overall survival (OS) 
was defined as the time from the date of ASCT to death from any cause. Patients still alive were 
censored at their last follow up. Progression-free survival (PFS) was defined as the time between 
transplantation and progression of disease or death, censoring patients who did not develop an event.  
The probabilities of OS and PFS were obtained using the Kaplan – Meier estimator and comparisons 
were made by Log-Rank test.  The probabilities of relapse (cumulative incidence of relapse, CIR) and 
death without prior relapse (non-relapse mortality, NRM) were calculated by the proper non-parametric 
estimator for outcomes with competing risk and comparisons were made by Gray test. These methods 
were also used to compute the cumulative incidence of second primary malignancy (SPM), considering 
death without prior SPM as a competing event. 
Cox proportional – hazards models were used to estimate adjusted hazard ratios (HR) for Mel140 
compared to Mel200 in terms of OS, PFS and CIR. Factors included in the multivariable analysis were age 
at transplant (<65 versus ≥65), renal function (normal glomerular filtration rate (GFR) >50mL/min versus 
impaired GFR ≤50mL/min), prior proteasome inhibitor treatment (yes versus no), status of disease at 
transplant (CR/VGPR versus PR versus <PR), Karnofsky performance score (<90 versus ≥90) and gender. 
Age was dichotomized with a cut-off of 65 years for comparability with other studies considering that 
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Martingale residuals analysis did not suggest other cut-off points (data not shown). There was no 
evidence that exclusion of missing values from multivariable analysis induced any bias in the estimation 
of regression coefficients (data not shown). 
In order to explore any possible modification of the effect of the melphalan dose in different subgroups, 
we then fit a secondary series of Cox models. Each model included melphalan dose, the selected 
adjustment variables, and the interaction between melphalan dose and one of the factors. This 
procedure returned estimated adjusted HRs for Mel140 compared to Mel200 in each subgroup defined 
by the selected factors, and the results are shown in forest plots.  
Due to the partial availability of International Staging System (ISS) and cytogenetic data, the interactions 
of ISS stage and chromosomal abnormalities with melphalan dose were analysed separately. 
Chromosomal abnormalities were classified as high-risk [t(4;14), t(14;16), and del(17)] or standard risk 
(all other cytogenetic findings).  
All p-values shown are from two-sided tests, and the reported confidence intervals (CI) refer to 95% 
boundaries. A p-value <.05 was regarded as statistically significant. A value up to 0.2 was used to 
determine the significance of interaction terms.  
 
Results 
Patient and treatment characteristics 
Patient- and treatment-related characteristics are shown in Table 1. Patients in the Mel140 group 
(n=245, 12.5%) were older than patients in the Mel200 group (n=1719, 87.5%) at the time of ASCT 
(median 64 years [range 27-73] versus 59 years [25-76]; p<.001). Compared to the Mel200 patients, 
those in the Mel140 group had light chain myeloma more often, were more often in ISS III, and were 
transplanted within 12 months from diagnosis less often. The two groups differed significantly in terms 
of body mass index, with a higher proportion of normal weight patients in the Mel140 group. Mel140 
patients had received proteasome inhibitor-containing induction therapy more often, and a greater 
proportion had a Karnofsky score of <90. Finally, more Mel140 patients had impaired renal function 
defined as a GFR of ≤50mL/min, and a greater proportion of Mel140 patients underwent ASCT in ≤PR.  
Efficacy  
OS was not significantly different between the two melphalan dose groups (Mel140, median not 
reached; 95% CI, 70.6 months to indeterminate; Mel200, 78 months; 95% CI, 74.0 months to 
indeterminate; Figure 1A). The overall adjusted hazard ratio (HR) for death from all causes was 1.10 
(95% CI, 0.79-1.54; p=.56) for the Mel140 group (Figure 1B). Multivariable analysis of different 
subgroups showed that age, renal function, prior proteasome inhibitor treatment, gender, or Karnofsky 
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score did not interact with OS in the melphalan dose groups (Figure 1B). However, disease status at 
transplant significantly modified the risk for death (p=.006). In patients transplanted in <PR, Mel200 was 
associated with a significant OS advantage (adjusted HR 0.5 for Mel200 vs. Mel140). In contrast, 
transplantation in VGPR/CR significantly favoured Mel140 (adjusted HR 2.02). Transplantation in PR did 
not modify the effect of melphalan dose on OS (adjusted HR 0.98).  
Median PFS was 29 months (95% CI, 24.6-33.7) in the Mel140 group and 26.3 months (95% CI, 24.6-
28.1) in the Mel200 group (Figure 2A). The adjusted HR for disease progression or death was 1.0 (95% 
CI, 0.79-1.25; p=.98) for the Mel140 group (Figure 2B). The multivariable models with interaction terms 
indicated that the HR of Mel200 versus Mel140 was not significantly modified by age, renal function, 
prior proteasome inhibitor treatment, gender, or Karnofsky score. However, in line with the OS analysis, 
there was a statistically significant change (p=.043) according to disease status at transplantation. In 
patients transplanted in ≤PR, Mel200 was associated with a significant PFS advantage (adjusted HR 0.54 
for Mel200 vs. Mel140), while Mel140 was linked to a numerically better outcome in those transplanted 
in VGPR/CR (adjusted HR 1.19). 
Cumulative incidence of relapse (CIR) at 3 years was not significantly different between the Mel140 
(55.1%; 95 % CI, 48.6-61.6) and Mel200 (59.9%; 95% CI, 57.5-62.3) groups (Figure 3A). The adjusted HR 
for relapse was 0.99 (95% CI, 0.78-1.25; p=.935) for Mel140 (Figure 3B). Subgroup analysis again 
showed a significant interaction of melphalan dose with disease status at the time of ASCT (p=.07), in 
that transplantation in ≤PR significantly favoured Mel200 (adjusted HR 0.56 for Mel200 vs. Mel140). The 
adjusted HRs for transplantation in PR and VGPR/CR were 0.98 and 1.2, respectively. 
Patients with high-risk chromosomal abnormalities had poorer OS and PFS, and a higher CIR, than those 
with other chromosomal aberrations, but we observed no statistically significant differences between 
Mel140 and Mel200 in high-risk or standard-risk patients (Figure 4). Similarly, while ISS stage was 
associated with OS, PFS, and CIR (Supplementary Figure 1), there was no interaction between 
melphalan dose and ISS stage (Supplementary Figure 2). 
Toxicity 
Non-relapse mortality (NRM) was not significantly different between the Mel140 and Mel200 groups (1-
year NRM 1.3% (95% CI, 0.0-2.7) and 0.9% (95% CI, 0.4 – 1.3); p=.20). Early NRM at 3 months post ASCT 
was not significantly different either (0.8 and 0.5%, respectively; p=.198). The main cause of death 
within 12 months of the transplant was relapse/progression in 77.8% of patients in the Mel140 group 
and 80.0% of patients in the Mel200 group. Median times to neutrophil and platelet recovery were not 
significantly different between the Mel140 and Mel200 groups (12 (Mel140 95% CI, 12-13; Mel200 95% 
CI, 12-12) days in both groups for neutrophil recovery (p=.283); 16 (95% CI, 15-17) and 15 (95% CI, 15-
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16) days for platelet recovery (p=.468). Second primary malignancy (SPM) rates 5 years post ASCT were 
very similar between the Mel140 (4.8%; 95% CI, 1.1-8.5) and Mel200 groups (4.8%; 95% CI, 3.6-6.0); 
p=.61).  
Discussion 
While Mel200 is generally recommended as standard conditioning prior to ASCT for MM
27
, Mel140 is 
often used in clinical practice in those perceived to be at risk of excess toxicity from Mel200. However, 
the effect of melphalan dose on transplant outcomes remains undetermined. Here we present data 
from a large number of patients undergoing ASCT as part of real-world treatment practice that suggest 
that remission status at the time of transplantation may favour Mel200 or Mel140 for key transplant 
outcomes including OS.  
One of the key findings of the study is that transplantation in <PR favoured Mel200 over Mel140 in 
terms of OS, PFS, and relapse risk. This may be explained by a greater dose-dependency of melphalan-
induced anti-myeloma effects in cells with limited chemo-sensitivity. However, we observed no benefit 
of Mel200 over Mel140 for patients with high risk chromosomal aberrations or higher ISS stage. Thus, 
while the better outcomes with Mel200 may at least partly be explained by the ability of the higher 
dose to overcome clinical resistance to induction therapies, Mel200 does not overcome the effects of 
poor-risk cytogenetics or advanced ISS stage. While the number of patients with known high-risk 
aberrations in our study was limited, the findings may be considered in line with preliminary data from 
an ongoing study that suggest a possible benefit of tandem ASCT for high-risk patients.
28
  It remains to 
be determined if molecular risk profiles other than those based on cytogenetic findings, or clinical 
features such as extra-medullary disease, favour Mel200.  These data were not available for analysis in 
this study. 
In contrast to poor clinical responders to induction therapy, transplantation in VGPR/CR appeared to 
favour Mel140. Considering that Mel200 was not linked to delayed haematopoietic recovery, increased 
early or late NRM, or SPM rate, an explanation for these findings is not apparent. It is conceivable that 
Mel200 resulted in moderately increased toxicities that were not clinically apparent or were not 
captured in our study, such as delayed physical recovery, or organ specific toxicities such as cardiac 
arrhythmias.
26
 Such effects may have affected physicians’ and patients’ attitude towards the nature, 
intensity, or duration of post-transplant treatment choices. However, they are not likely to fully explain 
the favourable outcomes linked to Mel140 in patients transplanted in VGPR/CR. Differences in 
melphalan pharmacokinetics in patient subgroups may also have accounted for some of the effects we 
observed, given that diverse factors such as creatinine clearance, fat free mass and haematocrit 
influence melphalan exposure.
29
 Melphalan exposure can vary considerably in myeloma patients 
treated with high-dose melphalan and ASCT, and higher exposure has been linked to greater toxicity 
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and better disease responses.
30
 In a recent study, high melphalan exposure was associated with 
significantly improved overall survival in myeloma patients undergoing ASCT.
31
 However, despite the 
clear survival benefit, melphalan exposure was not associated with time to progression or progression-
free survival, suggesting a possible link between melphalan exposure and long-term outcomes that is 
not directly attributed to immediate anti-myeloma effects. 
While some studies have suggested that older age and renal impairment can be linked to excess toxicity 
with Mel200, others have not reported such an association.
19,20,22-24,26,32-34
 The results of this study 
support the notion that older age and impaired renal function do not favour an attenuated melphalan 
dose in terms of NRM, haematopoietic recovery, or SPM rate. Moreover, we found no interaction of 
Karnofsky performance score with melphalan dose. However, the paucity in our study of data on 
comorbidities and frailty scores, and on the nature and grading of specific adverse events such as 
mucositis, means that we cannot exclude that Mel200 may be linked to an increase in some toxic effects 
in certain patients, or that Mel140 may have avoided such effects. Nonetheless, the data provide 
further support for the notion that ASCT is safe and effective in fit older patients, and they are in line 
with a recent study demonstrating the value of Mel140 tandem ASCT as an independent component of 
therapy in older patients.
35
 The application of objective criteria to determine patient fitness in the 
context of co-morbidities should aid optimal selection of both younger and older patients.
36-40
 
The CALM study is based on the retrospective analysis of registry data that were collected in a defined 
cohort of patients. Thus, the choice of Mel140 or Mel200 was made by transplant physicians and 
influenced or determined by local practice, thereby introducing a potential for biased treatment 
decisions. The paucity of data on post-transplant treatments including maintenance represents an 
additional limitation of the analysis. However, the large number of patients from multiple centres across 
Europe is likely to have formed a representative ‘real world’ sample of myeloma patients undergoing 
up-front ASCT. This notion is supported by the distribution of baseline clinical and cytogenetic features 
and the outcomes of patients with high compared to standard risk disease. Moreover, we applied 
robust statistical methods for the estimation of hazard ratios.  
Our data indicate that the vast majority of patients undergoing upfront ASCT in a real-world setting 
receive Mel200 conditioning, and that patients with poor clinical responses to induction therapies 
derive more benefit from Mel200 than from Mel140. However, the results of this study also indicate 
that transplantation in VGPR/CR may favour Mel140 over Mel200. While the reasons for this 
unexpected finding remain to be determined, the data raise the challenging question whether more 
patients should receive Mel140. This is relevant given that modern induction regimens achieve high 
VGPR/CR rates. The data presented here suggest that a randomized trial to define the optimal 
melphalan dose is warranted. Such a trial could also investigate the use of alternative conditioning 
approaches that incorporate novel agents 
41-44
 and the potential role of melphalan dosing in tandem 
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transplant approaches, which was not feasible in this analysis. In the meantime, while Mel200 should 
remain the standard of care for ASCT conditioning, Mel140-based transplants could be considered as a 
valid alternative to offer patients an effective combination of ASCT plus novel therapies.
45
 
In conclusion, our findings indicate that remission status at the time of a first ASCT may need to be 
considered when determining the melphalan dose.  
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Table 1 
    Mel200 Mel140   
Patient characteristics   n=1719 (87,5%) n=245 (12.5%) p-value 
Gender male 997 (58,0%) 144 (58,8%) 
0.818 
  
female 722 (42,0%) 101 (41,2%) 
Age at AHCT 
years 59 (25–76) 64 (27–73) 0.001* 
(median and range) 
Body mass index (BMI) underweight (BMI <18.5) 15 (1,1%) 4 (2,0%) 
0.004* 
  normal weight (18.5 ≤ BMI < 25) 484 (35,2%) 95 (48,5%) 
  overweight (25 ≤ BMI < 30) 587 (42,7%) 66 (33,7%) 
  obese (30 ≤ BMI < 35) 216 (15,7%) 22 (11,2%) 
  severely obese (BMI ≥ 35) 72 (5,2%) 9 (4,6%) 
Karnofsky score ≥ 90 1117 (71,9%) 139 (61,8%) 
0.002* 
  < 90 436 (28,1%) 86 (38,2%) 
Estimated GFR at AHCT  >50mL/min 1316 (96,3%) 123 (63,1%) 
0.001* 
  
 ≤50mL/min 51 (3,7%) 72 (36,9%) 
Myeloma characteristics 
        
Myeloma type common type 1328 (78,9%) 159 (65,7%) 
 0.001* 
  
light chain 328 (19,5%) 79 (32,6%) 
  
non-secretory 27 (1,6%) 4 (1,7%) 
ISS I 453 (43,1%) 31 (23,5%) 
0.001*   II 373 (35,5%) 48 (36,4%) 
  III 225 (21,4%) 53 (40,2%) 
High-risk chromosomal 
abnormalities
#
  
No 466 (85,8%) 78 (85,7%) 
0.979 
Yes 77 (14,2%) 13 (14,3%) 
Treatment-related 
parameters 
        
Pre-transplant treatment alkylating agent(s) 155 (10,6%) 7 (3,4%) 
0.001* 
  
alkylating agent(s) + proteasome inhibitor 236 (16,2%) 35 (17,1%) 
  
alkalyting agent(s) + IMiD(s) 322 (22,1%) 37 (18,0%) 
  
alkylating agent(s) + proteasome inhibitor + 
IMiD(s) 
88 (6,0%) 14 (6,8%) 
  
proteasome inhibitor  233 (16,0%) 44 (21,5%) 
  
IMiD(s) 92 (6,3%) 4 (2,0%) 
  
proteasome inhibitor + IMiD(s) 280 (19,2%) 54 (26,3%) 
  
other 50 (3,4%) 10 (4,9%) 
Time from diagnosis to AHCT < 12 months 1366 (79,5%) 179 (73,1%) 
0.022* 
  
> 12 months 353 (20,5%) 66 (26,9%) 
Disease status at AHCT CR/VGPR 765 (45,2%) 105 (43,9%) 
0.020* 
  
PR 797 (47,1%) 103 (43,1%) 
  
<PR 130 (7,7%) 31 (13,0%) 
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CD34+ cells infused (per kg) < 3 x 10
6
 405 (33,4%) 79 (40,9%) 
0.123   3 – 5 x 10
6
 508 (41,9%) 71 (36,8%) 
  > 5 x 10
6
 299 (24,7%) 43 (22,3%) 
 
Table 1: Patient and transplant-related characteristics. *Denotes statistically significant p-values (<.05); 
#
 
includes t(4;14), t(14;16), or del(17p). 
 
Figure legends 
 
Figure 1. Overall survival post ASCT for patients receiving melphalan conditioning of 140mg/m2 (Mel140) 
or 200mg/m2 (Mel200). (A) Kaplan-Meier curves. (B) Multivariate analyses. The overall HR and 
corresponding p-value (top line) refers to the comparison between Mel140 and Mel200 performed in a Cox 
model without interactions; the other HRs and p-values refer to interaction terms between melphalan dose 
and the indicated factors. All comparisons are adjusted for: age at transplant, renal function, prior 
proteasome inhibitor treatment, gender, status of disease, and Karnofsky score. 
 
 
Figure 2.  Progression-free survival post ASCT for patients receiving melphalan conditioning of 140 
(Mel140) or 200mg/m2 (Mel200). (A) Kaplan-Meier curves. (B) Multivariate analyses. The overall HR and 
corresponding p-value (top line) refers to the comparison between Mel140 and Mel200 performed in a Cox 
model without interactions; the other HRs and p-values refer to interaction terms between melphalan dose 
and the indicated factors. All comparisons are adjusted for: age at transplant, renal function, prior 
proteasome inhibitor treatment, gender, status of disease, and Karnofsky score. 
 
 
Figure 3. Cumulative incidence of relapse post ASCT for patients receiving melphalan conditioning of 140 
(Mel140) or 200mg/m2 (Mel200). (A) Kaplan-Meier curves. (B) Multivariate analyses. The overall HR and 
corresponding p-value (top line) refers to the comparison between Mel140 and Mel200 performed in a Cox 
model without interactions; the other HRs and p-values refer to interaction terms between melphalan dose 
and the indicated factors. All comparisons are adjusted for: age at transplant, renal function, prior 
proteasome inhibitor treatment, gender, status of disease, and Karnofsky score. 
 
           
Figure 4. Survival and relapse risk by cytogenetic risk. Overall survival (A), progression-free survival (B) and 
relapse risk (C) estimates and confidence intervals at 2 years post ASCT are shown for patients with high risk 
or standard risk chromosomal abnormalities. 
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Supplementary Figure 1: Overall survival, progression-free survival and relapse risk by ISS at diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2 
 
 
 
 
Supplementary Figure 2: Survival and relapse by International Staging System (ISS). Overall survival, 
progression-free survival and relapse risk in patients receiving a dose of melphalan equal to 140mg (Mel140) or 
200mg (Mel200) in ISS stage I, II or III. 
 
